1. Home
  2. JHS vs EQ Comparison

JHS vs EQ Comparison

Compare JHS & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo John Hancock Income Securities Trust

JHS

John Hancock Income Securities Trust

HOLD

Current Price

$11.00

Market Cap

127.2M

Sector

Finance

ML Signal

HOLD

EQ

Equillium Inc.

HOLD

Current Price

$2.97

Market Cap

129.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
JHS
EQ
Founded
N/A
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Finance Companies
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
127.2M
129.0M
IPO Year
1994
2018

Fundamental Metrics

Financial Performance
Metric
JHS
EQ
Price
$11.00
$2.97
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$8.00
AVG Volume (30 Days)
15.4K
845.0K
Earning Date
01-01-0001
05-25-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$41,095,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$10.74
$0.29
52 Week High
$12.09
$3.54

Technical Indicators

Market Signals
Indicator
JHS
EQ
Relative Strength Index (RSI) 50.50 52.86
Support Level $10.76 $1.68
Resistance Level $11.06 $3.15
Average True Range (ATR) 0.09 0.26
MACD 0.01 -0.01
Stochastic Oscillator 65.46 26.41

Price Performance

Historical Comparison
JHS
EQ

About JHS John Hancock Income Securities Trust

John Hancock Income Securities Trust is a United States-based closed-end diversified management investment company. Its main objective is to generate a high level of current income consistent with prudent investment risk. The fund invests its net assets (plus borrowings for investment purposes) in income securities, consisting of marketable corporate debt securities, governmental obligations, and cash and commercial paper. A majority of its net assets are invested in debt securities that are rated, at the time of acquisition, investment-grade or in unrated securities determined by the Fund's investment advisor or subadvisor to be of comparable credit quality.

About EQ Equillium Inc.

Equillium Inc is a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders with the mission to develop life-changing therapeutics for patients. It primary goal is to advance EQ504, a novel aryl hydrocarbon receptor, or AhR, modulator, into and through clinical development. The Company operates through a single operating and reportable segment focused on the business of developing novel therapies to treat severe autoimmune and inflammatory disorders, with the mission to develop life-changing therapeutics for patients. The Company manages all business activities on a consolidated basis.

Share on Social Networks: